Stock Ratings / Health Care / SMTI / financials

ZJYL (47) INGN (29) AVR (36) AGPU (37) ⌘ Pro Terminal →

Sanara MedTech Inc. (SMTI) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

Q: How profitable is Sanara MedTech Inc. (SMTI)?

In FY 2025 (10-K), SMTI converted $103.1M of revenue into a 92.7% gross margin, 7.1% operating margin, and $2.2M in free cash flow (2.1% FCF margin).

$32.92 +0.11% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Sanara MedTech Inc. (SMTI) carries a Roarable Rating of D+ (Sell) with 57/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D+ • SELL / AVOID Cap $302.4M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D+

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE-0.5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SMTI)Realized 20D OHLCV Swing Band: ±4%

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How SMTI Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$2.2M (2.1% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $65.0M

FY24

Rev $86.7M

FY25

Rev $103.1M

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$103.1M	92.7%	7.1%	$37.6M	$2.2M	16.3%
FY 2024	$86.7M	90.6%	1.5%	$9.7M	-$229.6K	1.8%
FY 2023	$65.0M	92%	-6.5%	$4.3M	-$3.2M	16.3%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SMTI)

✓Walkthrough of SMTI's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

SMTI // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +73.35%🛡️ HOLDING TREND SUPPORT

2026-10-30O $32.76H $33.19L $32.66C $32.92VOL 97.2K

RES: $36.29SUP: $31.64SMA50: $34.51SMA200: $25.48

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SMTI Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SMTI Butterfly Map → + Track SMTI →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

-5.2%/yr Implied 5Y Growth

vs. +19.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on SMTI today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SMTI. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for SMTI today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SMTI)

Health Care Rank #256 of 1016 ⚔️ ZJYL vs SMTI Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SMTI vs. ZJYL, INGN, AVR, AGPU)

Industry: Industrial Specialties (55 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Sanara MedTech Inc. (SMTI) ranks #256 by composite RQD confidence (57/100, grade D+) and #518 by equity capitalization ($302.4M). Within this direct 5-issuer industry benchmark cohort, SMTI leads on earnings valuation at 8.1x trailing P/E, while SMTI leads on capital efficiency and profitability with 16.3% ROIC and 92.7% gross margin. SMTI currently leads its immediate peer cohort in composite quantitative strength at 57/100 (D+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
SMTI ACTIVE Sanara MedTech Inc.	D+	57/100	8.1x	92.7%	16.3%	+0.11%	$302.4M	Benchmark Subject
ZJYL JIN MEDICAL INTERNATIONAL LTD. (Class A)	D	47/100	—	29.2%	—	-2.10%	$294.2M	/zjyl-vs-smti →
INGN Inogen Inc	E	29/100	8.5x	52.2%	-27.0%	+0.14%	$192.7M	/ingn-vs-smti →
AVR Anteris Technologies Global Corp.	D-	36/100	—	70.3%	-35.0%	+5.25%	$625.9M	/avr-vs-smti →
AGPU Axe Compute Inc.	D-	37/100	—	—	-35.0%	-2.01%	$101.7M	/agpu-vs-smti →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000714256

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Sanara MedTech Inc. (SMTI) reported GAAP revenue of $103.1M (+19.0% vs. FY2024 revenue of $86.7M , and +58.7% cumulative change since FY2023) , GAAP net income of $37.6M, operating cash flow of $6.8M, and free cash flow of $2.2M (+1041.1% YoY). On the balance sheet, SMTI closed FY2025 with $72.9M in total assets against $46.0M in total debt (Altman Z-Score: 3.25, Piotroski F-Score: 7/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$103.1M	$37.6M	$6.8M	$2.2M	$72.9M	$46.0M
FY2024 (FY)	2024-12-31	$86.7M	$9.7M	-$23.8K	-$229.6K	$88.1M	$30.7M
FY2023 (FY)	2023-12-31	$65.0M	$4.3M	-$3.2M	-$3.2M	—	—

3. SMTI Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SMTI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Sanara MedTech Inc. (NASDAQ: SMTI) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 57/100 at a spot price of $32.92 (+0.11% 1D, market cap $302.4M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 14/20. Across 1016 tracked Health Care issuers, SMTI ranks #256 in composite RQD confidence.

How does SMTI compare to ZJYL and INGN in the Health Care sector?

Within the Health Care sector (Industrial Specialties), SMTI carries a Roarable D+ (57/100 RQD), trailing P/E of 8.1x, gross margin of 92.7%, and ROIC of 16.3%. By comparison, ZJYL (JIN MEDICAL INTERNATIONAL LTD. (Class A)) holds a D grade (47/100 RQD, P/E N/A, ROIC —, cap $294.2M) and INGN (Inogen Inc) posts a E grade (29/100 RQD, P/E 8.5x, ROIC -27.0%, cap $192.7M). Among the 5-stock peer group, SMTI leads on earnings multiple (8.1x) while SMTI leads on capital efficiency (16.3% ROIC).

What are the biggest fundamental strengths and SEC risk factors for SMTI?

Per SMTI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000714256), Sanara MedTech Inc. generated $103.1M in revenue (+19.0% YoY), $37.6M in net income, and $2.2M in free cash flow against $72.9M in total assets and $46.0M in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is SMTI trading relative to its 50-day, 200-day, and 52-week technical levels?

SMTI last traded at $32.92 (+0.11% on volume of 35,140 shares), positioning the stock -4.61% below its 50-day simple moving average ($34.51) and +29.20% above its 200-day simple moving average ($25.48). Across its 52-week range of $16.05 to $35.52, SMTI sits at the 86.6% percentile with a 14-day RSI of 27.3 (OVERSOLD (<32)) and an implied next-earnings move of ±4.0% ($31.60 to $34.24).